Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation
Identifieur interne : 001F82 ( Main/Corpus ); précédent : 001F81; suivant : 001F83Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation
Auteurs : Boris Strasberg ; Alex Sagie ; Eldad Rechavia ; Amos Katz ; A. Ovsyscher ; Samuel Sclarovsky ; Jacob AgmonSource :
- Cardiovascular Drugs and Therapy [ 0920-3206 ] ; 1989-01-01.
Abstract
Summary: Three patients presented to the emergency room with atrial fibrillation and fast ventricular response with wide preexcited QRS complexes (Wolff-Parkinson-White syndrome). All three patients received intravenous verapamil (5–10mg). The first patient developed ventricular fibrillation requiring several defibrillations; the second patient developed severe hemodynamic deterioration requiring urgent cardioversion; in the third patient a marked increment in the ventricular response was noted, however, there was no hemodynamic impairment. Verapamil may cause detrimental results when given to patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. Its administration should therefore be considered as an absolute contraindication in these patients.
Url:
DOI: 10.1007/BF00133211
Links to Exploration step
ISTEX:F092A042232366C3AC33F4E3868688F296404F29Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation</title><author><name sortKey="Strasberg, Boris" sort="Strasberg, Boris" uniqKey="Strasberg B" first="Boris" last="Strasberg">Boris Strasberg</name><affiliation><mods:affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Sagie, Alex" sort="Sagie, Alex" uniqKey="Sagie A" first="Alex" last="Sagie">Alex Sagie</name><affiliation><mods:affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Rechavia, Eldad" sort="Rechavia, Eldad" uniqKey="Rechavia E" first="Eldad" last="Rechavia">Eldad Rechavia</name><affiliation><mods:affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Katz, Amos" sort="Katz, Amos" uniqKey="Katz A" first="Amos" last="Katz">Amos Katz</name><affiliation><mods:affiliation>Cardiology Division, Soroka Medical Center, Beersheva, Israel</mods:affiliation></affiliation></author><author><name sortKey="Ovsyscher, A" sort="Ovsyscher, A" uniqKey="Ovsyscher A" first="A." last="Ovsyscher">A. Ovsyscher</name><affiliation><mods:affiliation>Cardiology Division, Soroka Medical Center, Beersheva, Israel</mods:affiliation></affiliation></author><author><name sortKey="Sclarovsky, Samuel" sort="Sclarovsky, Samuel" uniqKey="Sclarovsky S" first="Samuel" last="Sclarovsky">Samuel Sclarovsky</name><affiliation><mods:affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Agmon, Jacob" sort="Agmon, Jacob" uniqKey="Agmon J" first="Jacob" last="Agmon">Jacob Agmon</name><affiliation><mods:affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F092A042232366C3AC33F4E3868688F296404F29</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1007/BF00133211</idno><idno type="url">https://api.istex.fr/document/F092A042232366C3AC33F4E3868688F296404F29/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001F82</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation</title><author><name sortKey="Strasberg, Boris" sort="Strasberg, Boris" uniqKey="Strasberg B" first="Boris" last="Strasberg">Boris Strasberg</name><affiliation><mods:affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Sagie, Alex" sort="Sagie, Alex" uniqKey="Sagie A" first="Alex" last="Sagie">Alex Sagie</name><affiliation><mods:affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Rechavia, Eldad" sort="Rechavia, Eldad" uniqKey="Rechavia E" first="Eldad" last="Rechavia">Eldad Rechavia</name><affiliation><mods:affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Katz, Amos" sort="Katz, Amos" uniqKey="Katz A" first="Amos" last="Katz">Amos Katz</name><affiliation><mods:affiliation>Cardiology Division, Soroka Medical Center, Beersheva, Israel</mods:affiliation></affiliation></author><author><name sortKey="Ovsyscher, A" sort="Ovsyscher, A" uniqKey="Ovsyscher A" first="A." last="Ovsyscher">A. Ovsyscher</name><affiliation><mods:affiliation>Cardiology Division, Soroka Medical Center, Beersheva, Israel</mods:affiliation></affiliation></author><author><name sortKey="Sclarovsky, Samuel" sort="Sclarovsky, Samuel" uniqKey="Sclarovsky S" first="Samuel" last="Sclarovsky">Samuel Sclarovsky</name><affiliation><mods:affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</mods:affiliation></affiliation></author><author><name sortKey="Agmon, Jacob" sort="Agmon, Jacob" uniqKey="Agmon J" first="Jacob" last="Agmon">Jacob Agmon</name><affiliation><mods:affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</mods:affiliation></affiliation><affiliation><mods:affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Cardiovascular Drugs and Therapy</title><title level="j" type="abbrev">Cardiovasc Drug Ther</title><idno type="ISSN">0920-3206</idno><idno type="eISSN">1573-7241</idno><imprint><publisher>Kluwer Academic Publishers</publisher><pubPlace>Dordrecht</pubPlace><date type="published" when="1989-01-01">1989-01-01</date><biblScope unit="volume">2</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="801">801</biblScope><biblScope unit="page" to="806">806</biblScope></imprint><idno type="ISSN">0920-3206</idno></series><idno type="istex">F092A042232366C3AC33F4E3868688F296404F29</idno><idno type="DOI">10.1007/BF00133211</idno><idno type="ArticleID">Art14</idno><idno type="ArticleID">BF00133211</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0920-3206</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Three patients presented to the emergency room with atrial fibrillation and fast ventricular response with wide preexcited QRS complexes (Wolff-Parkinson-White syndrome). All three patients received intravenous verapamil (5–10mg). The first patient developed ventricular fibrillation requiring several defibrillations; the second patient developed severe hemodynamic deterioration requiring urgent cardioversion; in the third patient a marked increment in the ventricular response was noted, however, there was no hemodynamic impairment. Verapamil may cause detrimental results when given to patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. Its administration should therefore be considered as an absolute contraindication in these patients.</div></front></TEI><istex><corpusName>springer</corpusName><author><json:item><name>Boris Strasberg</name><affiliations><json:string>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</json:string><json:string>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</json:string></affiliations></json:item><json:item><name>Alex Sagie</name><affiliations><json:string>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</json:string><json:string>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</json:string></affiliations></json:item><json:item><name>Eldad Rechavia</name><affiliations><json:string>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</json:string><json:string>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</json:string></affiliations></json:item><json:item><name>Amos Katz</name><affiliations><json:string>Cardiology Division, Soroka Medical Center, Beersheva, Israel</json:string></affiliations></json:item><json:item><name>Ilya A. Ovsyscher</name><affiliations><json:string>Cardiology Division, Soroka Medical Center, Beersheva, Israel</json:string></affiliations></json:item><json:item><name>Samuel Sclarovsky</name><affiliations><json:string>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</json:string><json:string>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</json:string></affiliations></json:item><json:item><name>Jacob Agmon</name><affiliations><json:string>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</json:string><json:string>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</json:string></affiliations></json:item></author><articleId><json:string>Art14</json:string><json:string>BF00133211</json:string></articleId><language><json:string>eng</json:string></language><abstract>Summary: Three patients presented to the emergency room with atrial fibrillation and fast ventricular response with wide preexcited QRS complexes (Wolff-Parkinson-White syndrome). All three patients received intravenous verapamil (5–10mg). The first patient developed ventricular fibrillation requiring several defibrillations; the second patient developed severe hemodynamic deterioration requiring urgent cardioversion; in the third patient a marked increment in the ventricular response was noted, however, there was no hemodynamic impairment. Verapamil may cause detrimental results when given to patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. Its administration should therefore be considered as an absolute contraindication in these patients.</abstract><qualityIndicators><score>3.243</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 778 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>775</abstractCharCount><pdfWordCount>2091</pdfWordCount><pdfCharCount>14086</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>96</abstractWordCount></qualityIndicators><title>Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation</title><genre><json:string>research-article</json:string></genre><host><volume>2</volume><pages><last>806</last><first>801</first></pages><issn><json:string>0920-3206</json:string></issn><issue>6</issue><subject><json:item><value>Cardiology</value></json:item></subject><journalId><json:string>10557</json:string></journalId><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1573-7241</json:string></eissn><title>Cardiovascular Drugs and Therapy</title><publicationDate>1989</publicationDate><copyrightDate>1989</copyrightDate></host><publicationDate>1989</publicationDate><copyrightDate>1989</copyrightDate><doi><json:string>10.1007/BF00133211</json:string></doi><id>F092A042232366C3AC33F4E3868688F296404F29</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/F092A042232366C3AC33F4E3868688F296404F29/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/F092A042232366C3AC33F4E3868688F296404F29/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/F092A042232366C3AC33F4E3868688F296404F29/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Kluwer Academic Publishers</publisher><pubPlace>Dordrecht</pubPlace><availability><p>SPRINGER</p></availability><date>1989</date></publicationStmt><notesStmt><note>Calcium Antagonists</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation</title><author corresp="yes"><persName><forename type="first">Boris</forename><surname>Strasberg</surname></persName><affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</affiliation><affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</affiliation></author><author><persName><forename type="first">Alex</forename><surname>Sagie</surname></persName><affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</affiliation><affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</affiliation></author><author><persName><forename type="first">Eldad</forename><surname>Rechavia</surname></persName><affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</affiliation><affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</affiliation></author><author><persName><forename type="first">Amos</forename><surname>Katz</surname></persName><affiliation>Cardiology Division, Soroka Medical Center, Beersheva, Israel</affiliation></author><author><persName><forename type="first">Ilya</forename><surname>Ovsyscher</surname></persName><affiliation>Cardiology Division, Soroka Medical Center, Beersheva, Israel</affiliation></author><author><persName><forename type="first">Samuel</forename><surname>Sclarovsky</surname></persName><affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</affiliation><affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</affiliation></author><author><persName><forename type="first">Jacob</forename><surname>Agmon</surname></persName><affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</affiliation><affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</affiliation></author></analytic><monogr><title level="j">Cardiovascular Drugs and Therapy</title><title level="j" type="abbrev">Cardiovasc Drug Ther</title><idno type="JournalID">10557</idno><idno type="pISSN">0920-3206</idno><idno type="eISSN">1573-7241</idno><idno type="IssueArticleCount">19</idno><idno type="VolumeIssueCount">6</idno><imprint><publisher>Kluwer Academic Publishers</publisher><pubPlace>Dordrecht</pubPlace><date type="published" when="1989-01-01"></date><biblScope unit="volume">2</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="801">801</biblScope><biblScope unit="page" to="806">806</biblScope></imprint></monogr><idno type="istex">F092A042232366C3AC33F4E3868688F296404F29</idno><idno type="DOI">10.1007/BF00133211</idno><idno type="ArticleID">Art14</idno><idno type="ArticleID">BF00133211</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1989</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Summary: Three patients presented to the emergency room with atrial fibrillation and fast ventricular response with wide preexcited QRS complexes (Wolff-Parkinson-White syndrome). All three patients received intravenous verapamil (5–10mg). The first patient developed ventricular fibrillation requiring several defibrillations; the second patient developed severe hemodynamic deterioration requiring urgent cardioversion; in the third patient a marked increment in the ventricular response was noted, however, there was no hemodynamic impairment. Verapamil may cause detrimental results when given to patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. Its administration should therefore be considered as an absolute contraindication in these patients.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>Medicine & Public Health</head><item><term>Cardiology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1989-01-01">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-1">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/F092A042232366C3AC33F4E3868688F296404F29/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Springer, Publisher found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Kluwer Academic Publishers</PublisherName><PublisherLocation>Dordrecht</PublisherLocation></PublisherInfo><Journal><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>10557</JournalID><JournalPrintISSN>0920-3206</JournalPrintISSN><JournalElectronicISSN>1573-7241</JournalElectronicISSN><JournalTitle>Cardiovascular Drugs and Therapy</JournalTitle><JournalAbbreviatedTitle>Cardiovasc Drug Ther</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Type="Secondary">Cardiology</JournalSubject></JournalSubjectGroup></JournalInfo><Volume><VolumeInfo VolumeType="Regular" TocLevels="0"><VolumeIDStart>2</VolumeIDStart><VolumeIDEnd>2</VolumeIDEnd><VolumeIssueCount>6</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular"><IssueInfo TocLevels="0"><IssueIDStart>6</IssueIDStart><IssueIDEnd>6</IssueIDEnd><IssueArticleCount>19</IssueArticleCount><IssueHistory><CoverDate><Year>1989</Year><Month>1</Month></CoverDate></IssueHistory><IssueCopyright><CopyrightHolderName>Kluwer Academic Publishers</CopyrightHolderName><CopyrightYear>1989</CopyrightYear></IssueCopyright></IssueInfo><Article ID="Art14"><ArticleInfo Language="En" ArticleType="OriginalPaper" NumberingStyle="Unnumbered" TocLevels="0" ContainsESM="No"><ArticleID>BF00133211</ArticleID><ArticleDOI>10.1007/BF00133211</ArticleDOI><ArticleSequenceNumber>14</ArticleSequenceNumber><ArticleTitle Language="En">Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation</ArticleTitle><ArticleCategory>Calcium Antagonists</ArticleCategory><ArticleFirstPage>801</ArticleFirstPage><ArticleLastPage>806</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2004</Year><Month>6</Month><Day>2</Day></RegistrationDate></ArticleHistory><ArticleCopyright><CopyrightHolderName>Kluwer Academic Publishers</CopyrightHolderName><CopyrightYear>1989</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants><ArticleContext><JournalID>10557</JournalID><VolumeIDStart>2</VolumeIDStart><VolumeIDEnd>2</VolumeIDEnd><IssueIDStart>6</IssueIDStart><IssueIDEnd>6</IssueIDEnd></ArticleContext></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1 Aff2" CorrespondingAffiliationID="Aff3"><AuthorName DisplayOrder="Western"><GivenName>Boris</GivenName><FamilyName>Strasberg</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1 Aff2"><AuthorName DisplayOrder="Western"><GivenName>Alex</GivenName><FamilyName>Sagie</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1 Aff2"><AuthorName DisplayOrder="Western"><GivenName>Eldad</GivenName><FamilyName>Rechavia</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff4"><AuthorName DisplayOrder="Western"><GivenName>Amos</GivenName><FamilyName>Katz</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff4"><AuthorName DisplayOrder="Western"><GivenName>Ilya</GivenName><GivenName>A.</GivenName><FamilyName>Ovsyscher</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1 Aff2"><AuthorName DisplayOrder="Western"><GivenName>Samuel</GivenName><FamilyName>Sclarovsky</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1 Aff2"><AuthorName DisplayOrder="Western"><GivenName>Jacob</GivenName><FamilyName>Agmon</FamilyName></AuthorName></Author><Affiliation ID="Aff1"><OrgDivision>Israel and Ione Massada Center for Heart Diseases</OrgDivision><OrgName>Beilinson Medical Center</OrgName><OrgAddress><City>Petah Tikva</City><Country>Israel</Country></OrgAddress></Affiliation><Affiliation ID="Aff2"><OrgName>Tel Aviv University Sackler School of Medicine</OrgName><OrgAddress><City>Tel Aviv</City><Country>Israel</Country></OrgAddress></Affiliation><Affiliation ID="Aff4"><OrgDivision>Cardiology Division</OrgDivision><OrgName>Soroka Medical Center</OrgName><OrgAddress><City>Beersheva</City><Country>Israel</Country></OrgAddress></Affiliation><Affiliation ID="Aff3"><OrgDivision>Massada Center for Heart Diseases</OrgDivision><OrgName>Beilinson Medical Center</OrgName><OrgAddress><Postcode>49100</Postcode><City>Petah Tikva</City><Country>Israel</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En"><Heading>Summary</Heading><Para>Three patients presented to the emergency room with atrial fibrillation and fast ventricular response with wide preexcited QRS complexes (Wolff-Parkinson-White syndrome). All three patients received intravenous verapamil (5–10mg). The first patient developed ventricular fibrillation requiring several defibrillations; the second patient developed severe hemodynamic deterioration requiring urgent cardioversion; in the third patient a marked increment in the ventricular response was noted, however, there was no hemodynamic impairment.</Para><Para>Verapamil may cause detrimental results when given to patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. Its administration should therefore be considered as an absolute contraindication in these patients.</Para></Abstract><KeywordGroup Language="En"><Heading>Key Words</Heading><Keyword>verapamil</Keyword><Keyword>Wolff-Parkinson-White</Keyword><Keyword>arrhythmias</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">Boris</namePart><namePart type="family">Strasberg</namePart><affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</affiliation><affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alex</namePart><namePart type="family">Sagie</namePart><affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</affiliation><affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eldad</namePart><namePart type="family">Rechavia</namePart><affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</affiliation><affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Amos</namePart><namePart type="family">Katz</namePart><affiliation>Cardiology Division, Soroka Medical Center, Beersheva, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ilya</namePart><namePart type="given">A.</namePart><namePart type="family">Ovsyscher</namePart><affiliation>Cardiology Division, Soroka Medical Center, Beersheva, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Samuel</namePart><namePart type="family">Sclarovsky</namePart><affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</affiliation><affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jacob</namePart><namePart type="family">Agmon</namePart><affiliation>Israel and Ione Massada Center for Heart Diseases, Beilinson Medical Center, Petah Tikva, Israel</affiliation><affiliation>Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper"></genre><originInfo><publisher>Kluwer Academic Publishers</publisher><place><placeTerm type="text">Dordrecht</placeTerm></place><dateIssued encoding="w3cdtf">1989-01-01</dateIssued><copyrightDate encoding="w3cdtf">1989</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Summary: Three patients presented to the emergency room with atrial fibrillation and fast ventricular response with wide preexcited QRS complexes (Wolff-Parkinson-White syndrome). All three patients received intravenous verapamil (5–10mg). The first patient developed ventricular fibrillation requiring several defibrillations; the second patient developed severe hemodynamic deterioration requiring urgent cardioversion; in the third patient a marked increment in the ventricular response was noted, however, there was no hemodynamic impairment. Verapamil may cause detrimental results when given to patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. Its administration should therefore be considered as an absolute contraindication in these patients.</abstract><note>Calcium Antagonists</note><relatedItem type="host"><titleInfo><title>Cardiovascular Drugs and Therapy</title></titleInfo><titleInfo type="abbreviated"><title>Cardiovasc Drug Ther</title></titleInfo><genre type="Journal" displayLabel="Archive Journal"></genre><originInfo><dateIssued encoding="w3cdtf">1989-01-01</dateIssued><copyrightDate encoding="w3cdtf">1989</copyrightDate></originInfo><subject><genre>Medicine & Public Health</genre><topic>Cardiology</topic></subject><identifier type="ISSN">0920-3206</identifier><identifier type="eISSN">1573-7241</identifier><identifier type="JournalID">10557</identifier><identifier type="IssueArticleCount">19</identifier><identifier type="VolumeIssueCount">6</identifier><part><date>1989</date><detail type="volume"><number>2</number><caption>vol.</caption></detail><detail type="issue"><number>6</number><caption>no.</caption></detail><extent unit="pages"><start>801</start><end>806</end></extent></part><recordInfo><recordOrigin>Kluwer Academic Publishers, 1989</recordOrigin></recordInfo></relatedItem><identifier type="istex">F092A042232366C3AC33F4E3868688F296404F29</identifier><identifier type="DOI">10.1007/BF00133211</identifier><identifier type="ArticleID">Art14</identifier><identifier type="ArticleID">BF00133211</identifier><accessCondition type="use and reproduction" contentType="copyright">Kluwer Academic Publishers</accessCondition><recordInfo><recordContentSource>SPRINGER</recordContentSource><recordOrigin>Kluwer Academic Publishers, 1989</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F82 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001F82 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:F092A042232366C3AC33F4E3868688F296404F29
|texte= Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation
}}
| This area was generated with Dilib version V0.6.23. |  |